{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T11:16:52Z","timestamp":1783336612744,"version":"3.54.6"},"reference-count":15,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T00:00:00Z","timestamp":1758326400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP22H02810"],"award-info":[{"award-number":["JP22H02810"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP23K06165"],"award-info":[{"award-number":["JP23K06165"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["23ek0310017h0003"],"award-info":[{"award-number":["23ek0310017h0003"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological Sciences"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jphs.2025.09.008","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T01:43:25Z","timestamp":1758591805000},"page":"252-255","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Dapagliflozin with losartan but not olmesartan has an add-on protective effect in experimental Alport syndrome"],"prefix":"10.1016","volume":"159","author":[{"given":"Jun","family":"Horizono","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keito","family":"Mizumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Ann","family":"Suico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shota","family":"Kaseda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Sannomiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruki","family":"Tsuhako","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimi","family":"Owaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoichi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Shiraga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riko","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Kumabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Shuto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Kai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.jphs.2025.09.008_bib1","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jphs.2025.09.008_bib2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.jphs.2025.09.008_bib3","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jphs.2025.09.008_bib4","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.jphs.2025.09.008_bib5","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1016\/j.ekir.2024.09.014","article-title":"SGLT2-Inhibition in patients with Alport syndrome","volume":"9","author":"Boeckhaus","year":"2024","journal-title":"Kidney Int Rep"},{"issue":"6","key":"10.1016\/j.jphs.2025.09.008_bib6","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1097\/01.ASN.0000130562.90255.8F","article-title":"Mouse model of X-linked Alport syndrome","volume":"15","author":"Rheault","year":"2004","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.jphs.2025.09.008_bib7","doi-asserted-by":"crossref","first-page":"7053","DOI":"10.1038\/s41598-021-86109-1","article-title":"Metformin ameliorates the severity of experimental Alport syndrome","volume":"11","author":"Omachi","year":"2021","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.jphs.2025.09.008_bib8","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1159\/000452588","article-title":"Olmesartan prevents microalbuminuria in db\/db diabetic mice through inhibition of Angiotensin II\/p38\/SIRT1-Induced podocyte apoptosis","volume":"41","author":"Gu","year":"2016","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.jphs.2025.09.008_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.175521","article-title":"Inhibition of SGLT2 co-transporter by dapagliflozin ameliorates tubular proteinuria and tubule-interstitial injury at the early stage of diabetic kidney disease","volume":"942","author":"Farias","year":"2023","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jphs.2025.09.008_bib10","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.curtheres.2013.02.002","article-title":"Olmesartan is more effective than other angiotensin receptor antagonists in reducing proteinuria in patients with chronic kidney disease other than diabetic nephropathy","volume":"74","author":"Ono","year":"2013","journal-title":"Curr Ther Res Clin Exp"},{"issue":"6","key":"10.1016\/j.jphs.2025.09.008_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2021.101285","article-title":"The diuretic effects of SGLT2 inhibitors: a comprehensive review of their specificities and their role in renal protection","volume":"47","author":"Delanaye","year":"2021","journal-title":"Diabetes Metab"},{"issue":"6","key":"10.1016\/j.jphs.2025.09.008_bib12","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/ckj\/sfy090","article-title":"The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study","volume":"11","author":"Herrington","year":"2018","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.jphs.2025.09.008_bib13","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.83353","article-title":"Empagliflozin reduces podocyte lipotoxicity in experimental Alport syndrome","volume":"12","author":"Ge","year":"2023","journal-title":"eLife"},{"issue":"5","key":"10.1016\/j.jphs.2025.09.008_bib14","doi-asserted-by":"crossref","first-page":"771","DOI":"10.34067\/KID.0000000000000425","article-title":"SGLT2 inhibitors and kidney protection: mechanisms beyond tubuloglomerular feedback","volume":"5","author":"Upadhyay","year":"2024","journal-title":"Kidney360"},{"issue":"2","key":"10.1016\/j.jphs.2025.09.008_bib15","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1053\/j.ajkd.2020.03.026","article-title":"Alport syndrome: achieving early diagnosis and treatment","volume":"77","author":"Kashtan","year":"2021","journal-title":"Am J Kidney Dis"}],"container-title":["Journal of Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347861325000945?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347861325000945?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T06:20:38Z","timestamp":1763446838000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347861325000945"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1347861325000945"],"URL":"https:\/\/doi.org\/10.1016\/j.jphs.2025.09.008","relation":{},"ISSN":["1347-8613"],"issn-type":[{"value":"1347-8613","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dapagliflozin with losartan but not olmesartan has an add-on protective effect in experimental Alport syndrome","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jphs.2025.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of Japanese Pharmacological Society.","name":"copyright","label":"Copyright"}]}}